Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARO-ENaC in healthy volunteers and cystic fibrosis patients
NCT04375514Phase 2Terminated
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Jul 2020
- Primary completion
- May 2021
- Modality
- Lipid-based Nanoparticles, Conjugated siRNA, Chemically Modified siRNA
- Countries
- 2
01
Overview
A Phase 2 trial of ARO-ENaC in cystic fibrosis (CF), sponsored by Arrowhead Pharmaceuticals. Started Jul 2020; status: terminated.
02
Drugs
ARO-ENaC
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT04375514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04375514.